Mendus AB (OSTO:IMMU) Moat Score: 0/10 (As of Jul. 05, 2026)


OSTO:IMMU Mendus AB OSTO:IMMU
27 GF Score
Price kr6.11
! 2 Warning Signs
View Full Analysis

What is Mendus AB Moat Score?

Mendus AB has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

Mendus AB has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Mendus AB might have No Moat - No discernible moat.

Mendus AB  (OSTO:IMMU) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Mendus AB Moat Score Related Terms

OSTO:IMMU
27GF Score
Mendus AB OSTO:IMMU
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mendus AB Business Description

Other Exchanges 1YG0:Germany
Address Vastra Tradgardsgatan 15, Stockholm, SWE, 11153
Mendus AB is a clinical-level biopharmaceutical company based on the company's allogeneic dendritic cell biology focused on the development of immunotherapies that address tumor recurrence and hard-to-treat established tumors. Its operations consist of research and development for pharmaceuticals. The company's Pipeline includes: Vididencel, and Ilixadencel.
27GF Score

Get the complete analysis for OSTO:IMMU

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr6.11
Price